| ATM | Ataxia telangiectasia mutated |
| alt-NHEJ | Alternative non-homologous end joining |
| B-NHEJ | Backup nonhomologous end-joining |
| BER | Base excision repair |
| 51BP1 | P51 binging protein 1 |
| c-NHEJ | Canonical non-homologous end joining |
| CtIP | BRCA1 C-terminal Interacting Protein |
| D-NHEJ | DNA-PK-mediated nonhomologous end-joining |
| DDR | DNA damage response |
| DSB | DNA double strand break |
| ESCC | Esophageal squamous cell carcinoma |
| FDA | Food and drug administration |
| HR | Homologous recombination |
| MMEJ | Microhomology-mediated end-joining |
| NHEJ | Nonhomologous end-joining |
| PARPi | Poly (ADP-ribose) polymerase 1 inhibitor |
| Polθ | Polymerase theta |
| Polθi | Polymerase theta inhibitor |
| ROS | Reactive oxygen species |
| RBBP8 | Retinoblastoma binding protein 8 |
| RPA | Replication protein A |
| RIF1 | Replication timing regulatory factor 1 |
| SSA | Single strand annealing |
| SSB | Single strand break |
| ssDNA | Single stranded DNA |
| SL | Synthetic lethality |
| XPF | Xeroderma pigmentosum complementation group F |